Madison Vaccines Developing a Treatment for Early-Stage Prostate Cancer Patients
When prostate cancer is detected in men at an early stage, they can usually be cured if the tumours are removed early or if the prostate gland is removed or treated with radiation before the cancerous cells have a chance to spread. However, sometimes, cancerous prostate cells remain in the body and can spread. Often, these patients must undergo hormone deprivation to decrease testosterone levels, which can ultimately lead to the requirement for castration.
The Madison Vaccines pharmaceutical company is developing an early stage prostate cancer treatment for those whose prostate have been removed, but before the cancer has had the chance to spread around the body. This will hopefully prevent the need for any kind of hormone deprivation therapies or castration by aiding the patients immune system to recognise cancerous cells and destroy them.
This treatment is being developed in the form of a DNA plasmid vaccine, called MVI-816. It works by promoting the production of PAP protein (prostatic acid phosphatase) in the body, and the protein acts as an antigen to elicit an immune response against PAP, as has been shown in phase I trials.
The experimental vaccine will now move into phase II trials, to see if the immune response against PAP is powerful enough to stop the cancer from spreading. The therapeutic vaccine will, hopefully, stimulate the immune system to locate and attack remaining cancerous prostate cells that produce the PAP protein. In this way, reoccurring prostate cancer may be preventable in the near future.
Many DNA vaccine therapies that stimulate the bodies immune response to fight cancer have been developed since the 90’s, however, many of them fail to progress to later phase trials as drawbacks are encountered.
Read more about it here: Madison Vaccines Rides Immunotherapy Wave With Early-Stage Prostate Drug